Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TM, Laakso M, Kesäniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Burgess DC, et al. Among authors: hunt d. Eur Heart J. 2010 Jan;31(1):92-9. doi: 10.1093/eurheartj/ehp377. Epub 2009 Sep 29. Eur Heart J. 2010. PMID: 19797259 Clinical Trial.
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Tonkin A, Hunt D, Voysey M, Kesäniemi A, Hamer A, Waites J, Mahar L, Mann S, Glasziou P, Forder P, Simes J, Keech AC; FIELD Study Investigators. Tonkin A, et al. Among authors: hunt d. Am Heart J. 2012 Mar;163(3):508-14. doi: 10.1016/j.ahj.2011.12.004. Am Heart J. 2012. PMID: 22424024 Free article. Clinical Trial.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Keech A, et al. Among authors: d emden m, hunt d. Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2. Lancet. 2005. PMID: 16310551 Clinical Trial.
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A; LIPID Study Investigators. Colquhoun D, et al. Among authors: hunt d. Eur Heart J. 2004 May;25(9):771-7. doi: 10.1016/j.ehj.2004.03.013. Eur Heart J. 2004. PMID: 15120888 Clinical Trial.
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).
White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, Hunt D, Blankenberg S; LIPID Study Investigators. White HD, et al. Among authors: hunt d. J Am Coll Cardiol. 2014 Feb 4;63(4):345-54. doi: 10.1016/j.jacc.2013.08.1643. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24140630 Free article. Clinical Trial.
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators. Simes RJ, et al. Among authors: hunt d. Circulation. 2002 Mar 12;105(10):1162-9. doi: 10.1161/hc1002.105136. Circulation. 2002. PMID: 11889008
2,222 results